PATENT ATTORNEY DOCKET NO. 50412/021002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Larsen et al.

Confirmation No.:

9323

Serial No.:

10/646,294

Art Unit:

1654

Filed:

August 22, 2003

Examiner:

R. Teller

Customer No.:

21559

Title:

MEDICAL USES OF INTERCELLULAR COMMUNICATION

FACILITATING COMPOUNDS

REPLY TO RESTRICTION REQUIREMENT

In reply to the Restriction Requirement that was mailed in connection with the above-captioned case on October 9, 2008, Applicants elect Groups I-IV, claims 103, 105, and 108-125. These claims are drawn to the compounds hydroxyacetyl-Asn-Tyr-NH₂, hydroxyacetyl-Asn-Tyr-OH, hydroxyacetyl-Gly-Tyr-NH₂, and hydroxyacetyl-Gly-Tyr-OH. In the concurrently filed Preliminary Amendment, claim 103 has been amended to recite only these four compounds. The election is made without traverse.

In the Restriction Requirement, the Office asserts that the inventions are unrelated and that a serious search and examination burden would result if restriction were not required. Applicants respectfully disagree. In the Office action mailed October 4, 2007, the Office allowed claim 103, which recites the four compounds now elected. Thus, examination of claim 103 would not present an undue burden on the Office. Applicants therefore request examination of claim 103 and dependent claims 105 and 108-125.

To the extent that the Office disagrees, Applicants elect Groups I and II, claims 103, 105, and 108-117. These claims are directed to hydroxyacetyl-Asn-Tyr-NH₂ and hydroxyacetyl-Asn-Tyr-OH. This election is made with traverse. Examination of these compounds would not present an undue burden on the Office. As set forth above, claim 103, which recites these compounds, was previously allowed. In addition, a search for these two compounds has been performed, as stated on page 2 of the Office action mailed October 4, 2007. Thus, examination of claims 103, 105, and 108-117 would likewise not present an undue burden on the Office.

To the extent that the Office requires election of a single compound, applicants elected Group I, claims 103, 105, and 108-113, directed to hydroxyacetyl-Asn-Tyr-NH₂. This election is made with traverse, for the reasons outlined above.

If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Date

Clark & Elbing LLP 101 Federal Street

Boston, MA 02110

Telephone: 617-428-0200 Facsimile: 617-428-7045

Respectfully submitted,

Kristina Bicker-Brady, Ph.D.

Reg. No. 39,109